Izalontamab Brengitecan Earns FDA Breakthrough Designation in EGFR+ NSCLC

3 months ago 62

The FDA designates iza-bren as a breakthrough therapy for advanced EGFR-mutant NSCLC, promising improved outcomes for patients with limited options.

1. Homepage
2. Lung Cancer
3. Izalontamab Brengitecan Earns FDA Breakthrough Designation in EGFR+ NSCLC